Lobe Sciences (LOBE) AI Stock Analysis

• Market Cap: C$16.17M
• Dividend Yield: N/A
• Average Volume (3M): 19.65K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.18
• Revenue Growth: -100.00%
• EPS Growth: -8.70%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 269,487,120
• 10 Day Avg. Volume: 13,139
• 30 Day Avg. Volume: 19,648
• PEG Ratio: 0.13
• Price to Book (P/B): 2.94
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.89
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: C$0.06 ▲(3.33% Upside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is constrained primarily by weak financial performance (no revenue, ongoing losses, and persistent cash burn), with only modest current leverage as a partial offset. Technicals add downside bias with the price below key moving averages and a negative MACD, while valuation provides limited support due to negative earnings and no dividend yield data.

Positive Factors

Modest leverage / improving balance sheet

Reported modest debt relative to equity in recent periods reduces near-term financing pressure versus highly leveraged peers. That lower leverage improves financial flexibility to fund R&D over the next several months and reduces default risk while the company pursues program milestones.

Improving cash-flow trend

Although absolute cash flow remains negative, the TTM improvement in free cash flow signals operational trends heading the right way. Sustained improvement can extend runway, lower near-term funding needs, and make future financing less dilutive if the trend continues over multiple quarters.

Focused CNS / psychedelic R&D and IP

Concentration on CNS and psychedelic-related therapeutics positions the company in a structural growth niche with rising scientific and commercial interest. Durable value could emerge from proprietary IP or successful clinical data, enabling licensing or partnerships that strengthen long-term commercial optionality.

Negative Factors

No revenue; persistent operating losses

The company operates with no recurring revenue and sizable operating losses, meaning it remains research-stage and unable to self-fund development. Over 2-6 months this structurally limits internal runway, forces reliance on external capital, and raises execution risk if fundraising stalls.

Sustained negative operating and free cash flow

Persistent cash burn requires repeated financing rounds or partnerships, increasing dilution risk and management distraction. Until FCF turns sustainably positive, cash constraints will limit trial progression, hiring, and commercialization activities, affecting medium-term ability to execute strategy.

Historical equity instability and prior negative equity

Past periods of negative equity indicate prior recapitalizations or losses that eroded shareholder value. That history signals elevated likelihood of future dilution or restructuring under stress, which undermines investor confidence and can complicate long-term financing and partnership negotiations.

Lobe Sciences Business Overview & Revenue Model

Company Description

Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. It develops psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder, as well as devices for the efficient application of medications. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.

How the Company Makes Money

Lobe Sciences generates revenue primarily through the development and commercialization of its proprietary therapeutic products. The company's revenue model is based on advancing its research and development pipeline to create marketable treatments for mental health disorders. It engages in partnerships and collaborations with other biotechnology firms, research institutions, and healthcare providers to enhance its research capabilities and facilitate the commercialization process. Additional revenue streams may include licensing agreements, joint ventures, and strategic alliances that enable the company to leverage its intellectual property and technological advancements. Significant factors contributing to Lobe Sciences' earnings include successful clinical trials, regulatory approvals, and the establishment of distribution channels for its therapeutic products.

Lobe Sciences Financial Statement Overview

Summary

Financial profile is weak: TTM shows no revenue with material operating and net losses, and cash flow remains meaningfully negative (ongoing cash burn). Balance sheet leverage is currently modest, but prior periods showed equity instability (including negative equity), indicating elevated financing and execution risk.

Income Statement

TTM (Trailing-Twelve-Months) results show no revenue and continued material operating losses (EBIT about -$5.0M; net loss about -$4.5M). The company’s revenue profile has been highly inconsistent over the last several years (including periods of near-zero sales and sharp declines), and profitability remains structurally negative with persistent losses across periods. The main positive is that the TTM net loss is slightly narrower than the prior annual period, but the lack of revenue and ongoing negative earnings keep income-statement quality very weak.

Balance Sheet

The balance sheet appears less leveraged in the most recent periods, with modest debt relative to equity in TTM (debt-to-equity ~0.19) and the latest annual period (~0.12), which helps reduce near-term financial risk. However, equity has been volatile and previously turned negative (2023–2024), indicating historical balance-sheet strain and potential dilution/recapitalization dynamics. Total assets increased sharply versus 2024, improving reported scale, but the multi-year equity instability is a key weakness.

Cash Flow

Cash generation remains a major concern: TTM (Trailing-Twelve-Months) operating cash flow and free cash flow are both meaningfully negative (about -$1.75M), and the company has consistently burned cash over multiple years. While free cash flow improved versus the prior annual period (positive growth rate in TTM), cash flow still does not cover losses and points to ongoing funding needs. The primary strength is the direction of improvement, but the absolute level of cash burn remains high.

Breakdown	Nov 2025	Nov 2024	Aug 2023	Nov 2022	Nov 2021
Income Statement
Total Revenue	0.00	136.21K	840.53K	0.00	0.00
Gross Profit	0.00	134.45K	772.83K	-10.22K	0.00
EBITDA	-4.27M	-4.12M	-4.40M	-11.96M	-6.16M
Net Income	-4.43M	-4.42M	-4.71M	-12.25M	-22.82M
Balance Sheet
Total Assets	7.59M	258.57K	2.30M	1.75M	12.10M
Cash, Cash Equivalents and Short-Term Investments	7.54M	237.77K	140.29K	907.54K	7.43M
Total Debt	273.35K	1.75M	332.64K	0.00	0.00
Total Liabilities	2.70M	3.37M	2.46M	1.30M	804.70K
Stockholders Equity	2.36M	-3.11M	-160.13K	445.69K	11.29M
Cash Flow
Free Cash Flow	-1.42M	-462.29K	-1.72M	-2.73M	-5.04M
Operating Cash Flow	-1.42M	-462.29K	-1.72M	-2.73M	-5.04M
Investing Cash Flow	6.56M	0.00	0.00	1.74M	1.07M
Financing Cash Flow	514.40K	563.51K	950.01K	753.12K	4.92M

Lobe Sciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.06
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:LOBE, the sentiment is Positive. The current price of 0.06 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.05, and above the 200-day MA of 0.04, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.56 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:LOBE.

Lobe Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OILS	55 Neutral	C$10.09M	-2.86	11.57%	―	-1.14%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AVCN	46 Neutral	C$23.88M	-5.08	-77.67%	―	2.41%	74.61%
LABS	45 Neutral	C$29.45M	-3.68	-19.10%	―	18.06%	34.58%
PCLO	44 Neutral	C$7.69M	5.19	―	―	15.64%	58.47%
GWAY	44 Neutral	C$19.93M	-44.16	-7.43%	―	19.66%	84.34%
LOBE	42 Neutral	C$16.17M	-2.55	―	―	-100.00%	-8.70%

Lobe Sciences Corporate Events

Lobe Sciences Ramps Up R&D on Psilocin-Based Therapeutic as Cash Position Remains Solid

Lobe Sciences reported first-quarter fiscal 2026 results showing a sharp ramp-up in research and development spending to approximately $982,000 as it accelerated work on lead candidate L-130 through its Cynaptec subsidiary, while maintaining a cash position of nearly $6 million, short-term investments of about $1 million, and net working capital just over $4 million. The higher R&D investment, focused on preclinical, clinical and regulatory activities for L-130 and progress on S-100 for sickle cell disease, contributed to a wider quarterly net loss of roughly $1.3 million, but management highlighted improved operating efficiency, tight cash controls and expanded scientific resources as evidence that the company is scaling its development pipeline in a disciplined manner ahead of planned Phase 1 and Phase 2 clinical work.

The most recent analyst rating on (TSE:LOBE) stock is a Hold with a C$0.06 price target. To see the full list of analyst forecasts on Lobe Sciences stock, see the TSE:LOBE Stock Forecast page.

Lobe Sciences Bolsters Board with Capital Markets Expert as It Builds on 2025 Momentum

Lobe Sciences has strengthened its board of directors with the appointment of corporate and securities lawyer Nick Karakochuk, whose expertise in mergers and acquisitions, capital markets, and governance is expected to support the company’s strategic growth initiatives following momentum built in fiscal 2025. As part of his appointment, Karakochuk received 3.5 million restricted share units, underscoring the company’s intent to align governance and capital markets capabilities with its clinical-stage biopharmaceutical ambitions in rare and orphan neurological and psychiatric diseases, including the development of its proprietary L-130 compound through majority-owned Cynaptec Pharmaceuticals.

The most recent analyst rating on (TSE:LOBE) stock is a Hold with a C$0.07 price target. To see the full list of analyst forecasts on Lobe Sciences stock, see the TSE:LOBE Stock Forecast page.

Lobe Sciences Strengthens Balance Sheet and Refocuses Pipeline After Leadership Overhaul

Lobe Sciences reported a substantial improvement in its fiscal 2025 financial position following a leadership transition and board renewal, with cash rising to $5.9 million, new short-term investments of $1.7 million, and working capital swinging from a deficit to a $5.2 million surplus, while eliminating its current portion of convertible notes and significantly reducing derivative liabilities. Despite a slightly higher net loss attributable to the parent company, the strengthened balance sheet, simplified corporate structure, and focused investment in core subsidiaries are expected to reduce liquidity risk and better support business development, as the company advances its L-130 CNS therapeutic program under Cynaptec and prioritizes S-100 for sickle cell disease through Altemia, positioning Lobe to pursue value-accretive transactions and partnerships aligned with shareholder interests.

The most recent analyst rating on (TSE:LOBE) stock is a Hold with a C$0.04 price target. To see the full list of analyst forecasts on Lobe Sciences stock, see the TSE:LOBE Stock Forecast page.